Ensuring HIV care to undocumented migrants in Israel: a public-private partnership case study.


Journal

Israel journal of health policy research
ISSN: 2045-4015
Titre abrégé: Isr J Health Policy Res
Pays: England
ID NLM: 101584158

Informations de publication

Date de publication:
13 11 2019
Historique:
received: 01 04 2019
accepted: 06 11 2019
entrez: 15 11 2019
pubmed: 15 11 2019
medline: 26 5 2020
Statut: epublish

Résumé

Undocumented migrants in Israel, mostly originating from HIV endemic countries, are not covered by Israel's universal healthcare coverage. We initiated a Public-Private Partnership (PPP) to handle this public health and humanitarian challenge. The PPP venture included the Ministry of Health (MoH), pharmaceutical companies, pharmacies, and specialized HIV clinics, the Israeli HIV Medical Society (from the Israel Medical Association), and non-governmental organizations. This study describes the national policy process in conceptualizing and implementing access to HIV services for undocumented migrants through a PPP, and analyzes the preliminary results. This case study describes the process of creating a temporary Public-Private Partnership to provide HIV care for undocumented migrants based on institutional records of the Department of Tuberculosis and AIDS (DTA) and memories and reflections from partners. This case was analyzed according to the OECD-DAC criteria for development assistance (relevance, effectiveness, efficiency, sustainability and impact). Demographic and serological data of patients referred between 2014 to 2018 were collected to monitor progress. and analyze preliminary medical and biological outcomes. Ethical approval was obtained from the Ministry of Health. Creating a policy to extend HIV care to undocumented migrants was a 15 year process that confronted several challenges within Israeli and international discourse, particularly concerning governmental response to the migration crisis. The use of a PPP model involving numerous stakeholders provided a solid, local feasibility demonstration that extending HIV care as a matter of policy would have positive implications for public health in Israel. During the first 2 years of the program (2014-2015), the MoH funded medical follow-up and the pharmaceutical companies provided antiretroviral treatment (ART) free of charge for only 100 patients at any given time, in addition to ART provided by the MoH for pregnant women. Since 2016, the MoH has fully covered this service and integrated it within the Israeli health system; this constitutes the major success of the PPP program. As of December 2018, the national program has monitored 350 patients and treated 316 (90.3%). The most prevalent disease present upon referral was Tuberculosis. To our knowledge, this study documents the first example of a successful PPP with government partnership in a high-income country to address undocumented migrants' lack of access to health services in general and HIV care in particular. In light of the intensification of North-South migration, this Israeli case study could be useful for other countries facing similar challenges. It also has lessons within Israel, as the country grapples with other health problems among uninsured communities.

Sections du résumé

BACKGROUND
Undocumented migrants in Israel, mostly originating from HIV endemic countries, are not covered by Israel's universal healthcare coverage. We initiated a Public-Private Partnership (PPP) to handle this public health and humanitarian challenge. The PPP venture included the Ministry of Health (MoH), pharmaceutical companies, pharmacies, and specialized HIV clinics, the Israeli HIV Medical Society (from the Israel Medical Association), and non-governmental organizations. This study describes the national policy process in conceptualizing and implementing access to HIV services for undocumented migrants through a PPP, and analyzes the preliminary results.
METHODS
This case study describes the process of creating a temporary Public-Private Partnership to provide HIV care for undocumented migrants based on institutional records of the Department of Tuberculosis and AIDS (DTA) and memories and reflections from partners. This case was analyzed according to the OECD-DAC criteria for development assistance (relevance, effectiveness, efficiency, sustainability and impact). Demographic and serological data of patients referred between 2014 to 2018 were collected to monitor progress. and analyze preliminary medical and biological outcomes. Ethical approval was obtained from the Ministry of Health.
RESULTS
Creating a policy to extend HIV care to undocumented migrants was a 15 year process that confronted several challenges within Israeli and international discourse, particularly concerning governmental response to the migration crisis. The use of a PPP model involving numerous stakeholders provided a solid, local feasibility demonstration that extending HIV care as a matter of policy would have positive implications for public health in Israel. During the first 2 years of the program (2014-2015), the MoH funded medical follow-up and the pharmaceutical companies provided antiretroviral treatment (ART) free of charge for only 100 patients at any given time, in addition to ART provided by the MoH for pregnant women. Since 2016, the MoH has fully covered this service and integrated it within the Israeli health system; this constitutes the major success of the PPP program. As of December 2018, the national program has monitored 350 patients and treated 316 (90.3%). The most prevalent disease present upon referral was Tuberculosis.
CONCLUSIONS
To our knowledge, this study documents the first example of a successful PPP with government partnership in a high-income country to address undocumented migrants' lack of access to health services in general and HIV care in particular. In light of the intensification of North-South migration, this Israeli case study could be useful for other countries facing similar challenges. It also has lessons within Israel, as the country grapples with other health problems among uninsured communities.

Identifiants

pubmed: 31722734
doi: 10.1186/s13584-019-0350-4
pii: 10.1186/s13584-019-0350-4
pmc: PMC6854724
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

80

Commentaires et corrections

Type : CommentIn

Références

Int J STD AIDS. 2004 Oct;15(10):691-6
pubmed: 15479507
Eur J Public Health. 2013 Dec;23(6):1039-45
pubmed: 23002238
Harefuah. 2003 Sep;142(8-9):632-5, 644
pubmed: 14518170
PLoS Med. 2011 May;8(5):e1001034
pubmed: 21629681
Infection. 2014 Oct;42(5):859-67
pubmed: 24973981
Isr J Health Policy Res. 2017 Nov 15;6(1):61
pubmed: 29141680
Health Soc Care Community. 2018 Jan;26(1):65-71
pubmed: 28608467
Soc Sci Med. 2010 Jan;70(2):329-36
pubmed: 19892452
Int J Tuberc Lung Dis. 2003 Sep;7(9):828-36
pubmed: 12971665
Am J Public Health. 2007 Jan;97(1):19-25
pubmed: 17138922
BMJ Open. 2013 Jul 06;3(7):
pubmed: 23833144
J Health Polit Policy Law. 2012 Feb;37(1):37-67
pubmed: 22003101
Bull World Health Organ. 2001;79(8):713-20
pubmed: 11545327
Health Aff (Millwood). 2016 Nov 1;35(11):1999-2004
pubmed: 27834239

Auteurs

Daniel Chemtob (D)

Department of Tuberculosis and AIDS, Israeli Ministry of Health, Jerusalem, Israel. daniel.chemtob@moh.gov.il.
Members of the ad hoc Health Committee of the Program, Jerusalem, Israel. daniel.chemtob@moh.gov.il.
Faculty of Medicine, Braun School of Public Health & Community Medicine, Hebrew University-Hadassah Medical School, Jerusalem, Israel. daniel.chemtob@moh.gov.il.

Rivka Rich (R)

Department of Tuberculosis and AIDS, Israeli Ministry of Health, Jerusalem, Israel.

Neta Harel (N)

Department of Tuberculosis and AIDS, Israeli Ministry of Health, Jerusalem, Israel.

Nechama Averick (N)

Department of Tuberculosis and AIDS, Israeli Ministry of Health, Jerusalem, Israel.

Eyal Schwartzberg (E)

Division of Pharmaceutics, Jerusalem, Israel.

Israel Yust (I)

Members of the ad hoc Health Committee of the Program, Jerusalem, Israel.

Shlomo Maayan (S)

Members of the ad hoc Health Committee of the Program, Jerusalem, Israel.

Itamar Grotto (I)

Former Head of Public Health Services, Jerusalem, Israel.

Ronni Gamzu (R)

Former Director General, Ministry of Health, Jerusalem, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH